- Khiron's largest shipment to date of EU-GMP certified medical
cannabis product arrives in Germany
- Khiron 20/1, a THC-dominant Cannabis flower, becomes
second Khiron-branded product to launch in Germany, having been prescribed in the UK
- 36.6kg shipment expected to have positive impact on Q2 2021
medical cannabis sales in Europe
- German medical cannabis market positioned for significant
growth with national insurance coverage and an estimated patient
base of over 100,000
TORONTO, June 8, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a vertically
integrated medical cannabis leader with core operations in
Latin America and Europe, is pleased to announce the receipt of
the Company's largest ever shipment of EU-GMP certified medical
cannabis product for distribution and sale into the German
market.
Recently, Khiron's German distribution partner, Nimbus Health
GmbH, received approximately 36kg of Khiron 20/1 medical cannabis
product, a THC-dominant cannabis flower product which has been
prescribed to patients in the UK since July
2020. The new product increases the Company's German medical
cannabis offering, which now includes both THC-dominant and
CBD-dominant Cannabis products. As a result of the
shipment, the Company expects to increase its European medical
cannabis sales in the second quarter of 2021.
"As we launch another new product into Germany and more than triple our shipment
volumes, our European team continues to demonstrate strong
execution and leadership. In line with our Mission of improving
patients' lives through medical cannabis, we continue to expand our
offering of EU-GMP cannabinoid-based medicines. Simultaneously, we
are developing additional products based on our Colombian extracts,
whose efficacy and safety are backed by real-world evidence from
over 20,000 prescriptions," comments Alvaro
Torres, CEO and Director.
Khiron's European product portfolio now includes both
THC-dominant and CBD-dominant cannabis flower products available
for sale in Germany and the UK,
two of the largest chronic pain markets in Europe. Over the coming months, the Company
plans to increase patient access by expanding its product offering
and medical education initiatives.
About Khiron Life Sciences Corp.
Khiron is a leading
vertically integrated medical cannabis company with core operations
in Latin America and Europe. Leveraging wholly-owned medical health
centres and proprietary telemedicine platforms, Khiron combines a
patient-oriented approach, physician education programs, scientific
expertise, product innovation, and agricultural infrastructure to
drive prescriptions and brand loyalty with patients worldwide. The
Company has a sales presence in Colombia, Peru, Germany
and the UK, and is positioned to commence sales in Mexico and Brazil in 2021. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
Investor Contact:
Paola Ricardo
E: investors@khiron.ca
T: +1 (647) 556-5750
Media Contact:
Peter
Leis
Europe Communications
E: pleis.ext@khiron.ca
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-receives-its-largest-european-medical-cannabis-shipment-to-date-301307974.html
SOURCE Khiron Life Sciences Corp.